These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 747176)

  • 21. Naltrexone in the treatment of opiate dependence.
    Resnick RB; Washton AM; Thomas MA; Kestenbaum RS
    NIDA Res Monogr; 1978; (19):321-32. PubMed ID: 218108
    [No Abstract]   [Full Text] [Related]  

  • 22. Predictors of favorable outcome following naltrexone treatment.
    Greenstein RA; Evans BD; McLellan AT; O'Brien CP
    Drug Alcohol Depend; 1983 Oct; 12(2):173-80. PubMed ID: 6653389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methadone and naltrexone in the treatment of heroin dependence.
    Greenstein RA; Resnick RB; Resnick E
    Psychiatr Clin North Am; 1984 Dec; 7(4):671-9. PubMed ID: 6522309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple family therapy and naltrexone in the treatment of opiate dependence.
    Anton RF; Hogan I; Jalali B; Riordan CE; Kleber HD
    Drug Alcohol Depend; 1981 Sep; 8(2):157-68. PubMed ID: 7318681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The treatment of heroin addiction: naltrexone alone and with behavior therapy.
    Callahan EJ; Rawson RA; McCleave B; Arias R; Glazer M; Liberman RP
    Int J Addict; 1980 Aug; 15(6):795-807. PubMed ID: 7461877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Naltrexone treatment of heroin addiction: efficacy and safety in a double-blind dosage comparison.
    Judson BA; Carney TM; Goldstein A
    Drug Alcohol Depend; 1981 Jul; 7(4):325-46. PubMed ID: 7023894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of naltrexone to extinguish opioid-conditioned responses.
    O'Brien CP; Childress AR; McLellan AT; Ternes J; Ehrman RN
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):53-6. PubMed ID: 6381473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of contingent payment on compliance with a naltrexone regimen.
    Grabowski J; O'Brien CP; Greenstein R; Ternes J; Long M; Steinberg-Donato S
    Am J Drug Alcohol Abuse; 1979; 6(3):355-65. PubMed ID: 539577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naltrexone for heroin addiction: encouraging results from Italy.
    Schifano F; Marra R
    Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):144-6. PubMed ID: 2338367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of the National Institute on Drug Abuse in the development of naltrexone.
    Ginzburg HM; Glass WJ
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):4-6. PubMed ID: 6088469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Detoxification treatment with naltrexone in opiate dependence].
    Ochoa Mangado E; López-Ibor Aliño JJ; Pérez de los Cobos Peris JC; Cebollada Gracia A
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1992; 20(5):215-29. PubMed ID: 1462806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Naltrexone maintenance for heroin dependence: uptake, attrition and retention.
    Tucker T; Ritter A; Maher C; Jackson H
    Drug Alcohol Rev; 2004 Sep; 23(3):299-309. PubMed ID: 15370010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Naltrexone treatment in a jail work-release program.
    Brahen LS; Henderson RK; Capone T; Kordal N
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):49-52. PubMed ID: 6469937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modification of treatment compliance as a function of contingent payment manipulations.
    Grabowski J; O'Brien CP; Greenstein R; Long M; Steinberg-Donato S; Ternes J
    NIDA Res Monogr; 1979; 27():402-8. PubMed ID: 121360
    [No Abstract]   [Full Text] [Related]  

  • 35. Naltrexone study guidelines: good vehicle--wrong destination.
    Brahen LS
    Am J Drug Alcohol Abuse; 1975; 2(3-4):451-3. PubMed ID: 1227303
    [No Abstract]   [Full Text] [Related]  

  • 36. Narcotic antagonists: naltrexone progress report: introduction.
    Renault PF
    NIDA Res Monogr; 1976 Sep; (9):1-3. PubMed ID: 794713
    [No Abstract]   [Full Text] [Related]  

  • 37. Betting on change: modeling transitional probabilities to guide therapy development for opioid dependence.
    Carpenter KM; Jiang H; Sullivan MA; Bisaga A; Comer SD; Raby WN; Brooks AC; Nunes EV
    Psychol Addict Behav; 2009 Mar; 23(1):47-55. PubMed ID: 19290689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of narcotic antagonists (naltrexone) in an addiction treatment program.
    Lewis D; Hersch R; Black R; Mayer J
    NIDA Res Monogr; 1976 Sep; (9):99-105. PubMed ID: 794728
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical experiences with naltrexone in 370 detoxified addicts.
    Thomas M; Kauders F; Harris M; Cooperstein J; Hough G; Resnick R
    NIDA Res Monogr; 1976 Sep; (9):88-92. PubMed ID: 794726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Naltrexone: the clinical investigator's dilemma.
    Ling W
    NIDA Res Monogr; 1978; (19):308-14. PubMed ID: 106297
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.